Isodiol International Inc. Announces Launch of Market’s First Hops-Derived CBD Products

VANCOUVER, B.C., Oct. 23, 2017 -- Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and wellness products, is pleased to announce the launch of the market’s first non-cannabis, highly bioactive cannabinoid, CBD, derived from the hops plant; a globally accepted plant. The cannabinoids are derived using proprietary genetics and extraction technology that allow for the isolation of the cannabinoids and terpenes without denaturing the molecule.

Hops-derived cannabinoid products have shown a favorable response and promising results in independent clinical studies for various diseases. Sourcing natural, highly bioactive cannabinoids to supplement the endocannabinoid system in the human body is key to developing targeted health care remedies.

“The development of the technology to extract cannabinoids from a plant other than cannabis, without denaturing the molecule is an incredible achievement,” said Marcos Agramont, CEO of Isodiol International. “As the regulatory framework within the US continues to mature, the establishment of a new non-cannabis source of CBD and the continued growth of our International pharmaceutical footprint will differentiate Isodiol as the global leader.”

The Company will continue to collaborate with universities and alternative health facilities in the United States and overseas to validate the science. It anticipates products will be ready for distribution within the next 4 weeks.

This announcement is on the heels of the Company’s introduction of it’s Phytoceutical Division on September 5, 2017. The press release can be found here.

For more information on Isodiol, please visit www.isodiol.com

About Isodiol International Inc.

Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.

Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.

Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.

Join Us On Facebook: https://www.facebook.com/isodiol/
Twitter: @isodiol

ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director

INVESTOR RELATIONS:
[email protected]
www.isodiol.com

MEDIA CONTACT:
Carrie Booze
North 6th Agency
212-334-9753 ext.142
[email protected]

Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation, and does not intend, to update any forward looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release.